March 13, 2025 -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Acade

13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, has been granted another pivotal patent, further reinforcing its leadership in innate immune-based cell therapies and in vivo immune modulation. LIfT’s newly granted US patent (US 12,070,473 B2) secures robust protection for the treatment of cancer, including the use of granulocytes derived from haematopoietic stem cells (HSCs), induced pluripotent stem ce

March 12, 2025 -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented promising findings from a study exploring how treating asymptomatic cytomegalovirus (CMV) in people living with HIV may improve immune function and physical health. The results from study A5383 were shared as the oral abstract, “Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV” at the 2025 Conference on Retro

February saw the first approvals of several important new drugs. From South Korea’s first domestically developed and approved botulinum toxin type A product to GSK’s five-valent meningococcal conjugate vaccine and a recombinant chikungunya vaccine co-developed by Denmark and the U.S., these breakthroughs not only expand treatment options but also offer patients more effective therapeutic choices. Additionally, new treatments for tenosynovial giant cell tumor, neurofibromatosis type 1, tetanus, c

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia and nocturia In this study, daridorexant was safe and well tolerated, consistent with the well-documented safety profile observed in the Phase 3 studies in chronic insomnia. The data from the Phase 4 study is published in the Journal of Sleep Research On World Sleep Day, Idorsia unites with the Worl

March 14, 2025 -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). “Receiving orphan drug designation from the FDA underscores the growing n

No significant clinical adverse event observed in Phase 1clinical study Pharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy Study First patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at the Montreal Heart Institute March 13, 2025 -- COSCIENS Biopharma Inc., a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announce

March 13, 2025 -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia’s cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual trea

March 11, 2025 -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accounts for half of an esti

March 13, 2025 -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental